Characterization of angiotensin II molecular determinants involved in AT1 receptor functional selectivity

I Domazet, BJ Holleran, A Richard… - Molecular …, 2015 - ASPET
I Domazet, BJ Holleran, A Richard, C Vandenberghe, P Lavigne, E Escher, R Leduc
Molecular pharmacology, 2015ASPET
The octapeptide angiotensin II (AngII) exerts a variety of cardiovascular effects through the
activation of the AngII type 1 receptor (AT1), a G protein–coupled receptor. The AT1 receptor
engages and activates several signaling pathways, including heterotrimeric G proteins Gq
and G12, as well as the extracellular signal–regulated kinases (ERK) 1/2 pathway.
Additionally, following stimulation, β arrestin is recruited to the AT1 receptor, leading to
receptor desensitization. It is increasingly recognized that specific ligands selectively bind …
The octapeptide angiotensin II (AngII) exerts a variety of cardiovascular effects through the activation of the AngII type 1 receptor (AT1), a G protein–coupled receptor. The AT1 receptor engages and activates several signaling pathways, including heterotrimeric G proteins Gq and G12, as well as the extracellular signal–regulated kinases (ERK) 1/2 pathway. Additionally, following stimulation, βarrestin is recruited to the AT1 receptor, leading to receptor desensitization. It is increasingly recognized that specific ligands selectively bind and favor the activation of some signaling pathways over others, a concept termed ligand bias or functional selectivity. A better understanding of the molecular basis of functional selectivity may lead to the development of better therapeutics with fewer adverse effects. In the present study, we developed assays allowing the measurement of six different signaling modalities of the AT1 receptor. Using a series of AngII peptide analogs that were modified in positions 1, 4, and 8, we sought to better characterize the molecular determinants of AngII that underlie functional selectivity of the AT1 receptor in human embryonic kidney 293 cells. The results reveal that position 1 of AngII does not confer functional selectivity, whereas position 4 confers a bias toward ERK signaling over Gq signaling, and position 8 confers a bias toward βarrestin recruitment over ERK activation and Gq signaling. Interestingly, the analogs modified in position 8 were also partial agonists of the protein kinase C (PKC)–dependent ERK pathway via atypical PKC isoforms PKCζ and PKCι.
ASPET